nach oben

Erschienen in:

01.06.2015 | Original Research

The Effects of Atorvastatin on the Prevention of Osteoporosis and Dyslipidemia in the High-Fat-Fed Ovariectomized Rats

verfasst von: Sien Lin, Jianping Huang, Ziwei Fu, Yanlong Liang, Haiyou Wu, Liangliang Xu, Yuxin Sun, Wayne Y. W. Lee, Tie Wu, Ling Qin, Liao Cui, Gang Li

Erschienen in: Calcified Tissue International | Ausgabe 6/2015

Einloggen, um Zugang zu erhalten

Abstract

Previous studies reported that statins showed positive effects on bone in both human and animal models. This study aimed to investigate the effects of atorvastatin on the prevention of osteoporosis and dyslipidemia in ovariectomized rats fed with high-fat emulsion. The 3-month-old female rats were subjected to either sham operations (n = 8) or ovariectomized operations (OVX, n = 24). The OVX rats were orally administered deionized water (n = 8) or standardized high-fat emulsion without (n = 8) or with atorvastatin (n = 8). All rats were injected twice with calcein before sacrificed for the purpose of double in vivo labeling. After 12 weeks, all rats were sacrificed under anesthesia. Biochemistry, histomorphometry, mechanical test, micro-computed tomography analysis, mechanical test, histology, and component analysis were performed. We found that high-fat emulsion significantly decreased body weight, bone formation, collagen content of bone, and bone biomechanics, while increased blood, liver, and bone marrow lipids. Atorvastatin treatment prevented dyslipidemia, reversed hepatic steatosis, optimized composition of bone, and improved bone mechanical properties. The current study provided further evidence that atorvastatin might be useful for the treatment of osteoporotic patients with dyslipidemia.

Xia WB, He SL, Xu L, Liu AM, Jiang Y, Li M, Wang O, Xing XP, Sun Y, Cummings SR (2012) Rapidly increasing rates of hip fracture in Beijing, China. J Bone Miner Res 27:125–129CrossRefPubMed

Cooper C, Cole ZA, Holroyd CR, Earl SC, Harvey NC, Dennison DM, Melton LJ, Cummings SR, Kanis JA (2011) Secular trends in the incidence of hip and other osteoporotic fractures. Osteoporos Int 22:1277–1288CrossRefPubMedCentralPubMed

Wohl GR, Loehrke L, Watkins BA, Zernicke RF (1998) Effects of high-fat diet on mature bone mineral content, structure, and mechanical properties. Calcif Tissue Int 63:74–79CrossRefPubMed

van Beek E, Pieterman E, Cohen L, Lowik C, Papapoulos S (1999) Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates. Biochem Biophys Res Commun 264:108–111CrossRefPubMed

Fisher JE, Rogers MJ, Halasy JM, Luckman SP, Hughes DE, Masarachia PJ, Wesolowski G, Russell RG, Rodan GA, Reszka AA (1999) Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proc Natl Acad Sci USA 96:133–138CrossRefPubMedCentralPubMed

Halcox JP, Deanfield JE (2004) Beyond the laboratory: clinical implications for statin pleiotropy. Circulation 109:II42–II48CrossRefPubMed

Maritz FJ, Conradie MM, Hulley PA, Gopal R, Hough S (2001) Effect of statins on bone mineral density and bone histomorphometry in rodents. Arterioscler Thromb Vasc Biol 21:1636–1641CrossRefPubMed

Drake Matthew T, Clarke Bart L, Khosla Sundeep (2008) Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc 83:1032–1045CrossRefPubMedCentralPubMed

Grasser WA, Baumann AP, Petras SF, Harwood HJ Jr, Devalaraja R, Renkiewicz R, Baragi V, Thompson DD, Paraklar VM (2003) Regulation of osteoclast differentiation by statins. J Musculoskelet Neuronal Interact 3:53–62PubMed

10.

Chen PY, Sun JS, Tsuang YH, Chen MH, Weng PW, Lin FH (2010) Simvastatin promotes osteoblast viability and differentiation via Ras/Smad/Erk/BMP-2 signaling pathway. Nutr Resm 30:191–199CrossRef

11.

Maeda T, Matsunuma A, Kawane T, Horiuchi N (2001) Simvastatin promotes osteoblast differentiation and mineralization in MC3T3-E1 cells. Biochem Biophys Res Commun 280:874–877CrossRefPubMed

12.

Chan KA, Andrade SE, Boles M, Buist DS, Chase GA, Donahue JG, Goodman MJ, Gurwitz JH, LaCroix AZ, Platt R (2000) Inhibitors of hydroxymethylglutaryl-coenzyme A reductase and risk of fracture among older women. Lancet 355:2185–2188CrossRefPubMed

13.

Uysal AR, Delibasi T, Erdogan MF, Kamel N, Baskal N, Tonyukuk V, Corapcioglu D, Güllü S, Erdogan G (2007) Effect of simvastatin use on bone mineral density in women with type 2 diabetes. Endocr Pract 13:114–116CrossRefPubMed

14.

Majima T, Komatsu Y, Fukao A, Ninomiya K, Matsumura T, Nakao K (2007) Short term effects of atorvastatin on bone turnover in male patients with hypercholesterolemia. Endocr J 54:145–151CrossRefPubMed

15.

Majima T, Shimatsu A, Komatsu Y, Satoh N, Fukao A, Ninomiya K, Matsumura T, Nakao K (2007) Shortterm effects of pitavastatin on biochemical markers of bone turnover in patients with hypercholesterolemia. Intern Med 46:1967–1973CrossRefPubMed

16.

Safaei H, Janghorbani M, Aminorroaya A, Amini M (2007) Lovastatin effects on bone mineral density in postmenopausal women with type 2 diabetes mellitus. Acta Diabetol 44:76–82CrossRefPubMed

17.

Schoofs MW, Sturkenboom MC, van der Klift M, Hofman A, Pols HA, Stricker BH (2004) HMG-CoA reductase inhibitors and the risk of vertebral fracture. J Bone Miner Res 19:1525–1530CrossRefPubMed

18.

Rejnmark L, Olsen ML, Johnsen SP, Vestergaard P, Sorensen HT, Mosekildeb L (2004) Hip fracture risk in statin users: a population-based Danish case-control study. Osteoporos Int 15:452–458PubMed

19.

Hatzigeorgiou C, Jackson JL (2005) Hydroxymethylglutaryl-coenzyme A reductase inhibitors and osteoporosis: a meta-analysis. Osteoporos Int 16:990–998CrossRefPubMed

20.

Uzzan B, Cohen R, Nicolas P, Cucherat M, Perret GY (2007) Effects of statins on bone mineral density: a meta-analysis of clinical studies. Bone 40:1581–1587CrossRefPubMed

21.

Bone HG, Kiel DP, Lindsay RS, Lewiecki EM, Bolognese MA, Leary ET, Lowe W, McClung MR (2007) Effects of atorvastatin on bone in postmenopausal women with dyslipidemia: a double-blind, placebo-controlled, dose-ranging trial. J Clin Endocrinol Metab 92:4671–4677CrossRefPubMed

22.

Huang JH, Huang XH, Chen ZY, Zheng QS, Sun RY (2004) Dose conversion among different animals and healthy volunteers in pharmacological study. Chin J Clin Pharmacol Ther 9:1069–1072

23.

U.S. Food and Drug Administration (2005) FDA Guidance for industry and reviews estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers. Available from: http://www.fda.gov/downloads/Drugs/Guidances/UCM078932.pdf Accessed 07 May 2005

24.

Lin SE, Huang JP, Wu LZ, Wu T, Cui L (2013) Prevention of osteopenia and dyslipidemia in rats after ovariectomy with combined aspirin and low-dose diethylstilbestrol. Biomed Environ Sci 26:249–257PubMed

25.

Cui L, Li T, Liu Y, Li P, Xu B, Huang L, Chen Y, Liu Y, Tian X, Jee WS, Wu T (2012) Salvianolic acid B prevents bone loss in prednisone-treated rats through stimulation of osteogenesis and bone marrow angiogenesis. PLoS One 7:e34647CrossRefPubMedCentralPubMed

26.

Lin SE, Huang JP, Zheng L, Liu YZ, Liu GH, Li N, Wang KX, Zou LY, Wu T, Qin L, Cui L, Li G (2014) Glucocorticoid-induced osteoporosis in growing rats. Calcif Tissue Int 95:362–373CrossRefPubMed

27.

Dempster DW, Compston JE, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR, Parfitt AM (2013) Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 28:2–17CrossRefPubMedCentralPubMed

28.

Campbell GM, Bernhardt R, Scharnweber D, Boyd SK (2011) The bone architecture is enhanced with combined PTH and alendronate treatment compared to monotherapy while maintaining the state of surface mineralization in the OVX rat. Bone 49:225–232CrossRefPubMed

29.

Mahanti HS, Barnes RM (1983) Determination of major, minor and trace elements in bone by inductively-coupled plasma emission spectrometry. Anal Chim Acta 151:409–417CrossRef

30.

Little Tanya J, Feinle-Bisset Christine (2010) Oral and gastrointestinal sensing of dietary fat and appetite regulation in humans: modification by diet and obesity. Front Neurosci 4:178PubMedCentralPubMed

31.

Paquette A, Shinoda M, Rabasa Lhoret R, Prud’homme D, Lavoie JM (2007) Time course of liver lipid infiltration in ovariectomized rats: impact of a high-fat diet. Maturitas 58:182–190CrossRefPubMed

32.

Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ (2004) Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110:227–239CrossRefPubMed

33.

Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (2001) Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285:2486–2497CrossRef

34.

Stein EA (2003) The power of statins: aggressive lipid lowering. Clin Cardiol 26:III25–III31CrossRefPubMed

35.

Parhami F, Tintut Y, Beamer WG, Gharavi N, Goodman W, Demer LL (2001) Atherogenic high-fat diet reduces bone mineralization in mice. J Bone Miner Res 16:182–188CrossRefPubMed

36.

Cao JJ, Gregoire BR, Gao H (2009) High-fat diet decreases cancellous bone mass but has no effect on cortical bone mass in the tibia in mice. Bone 44:1097–1104CrossRefPubMed

37.

Patsch JM, Kiefer FW, Varga P, Pail P, Rauner M, Stupphann D, Resch H, Moser D, Zysset PK, Stulnig TM, Pietschmann P (2011) Increased bone resorption and impaired bone microarchitecture in short-term and extended high-fat diet-induced obesity. Metabolism 60:243–249CrossRefPubMed

38.

Seeman E, Delmas PD (2006) Bone quality–the material and structural basis of bone strength and fragility. N Engl J Med 354:2250–2261CrossRefPubMed

39.

Kaji H, Kanatani M, Sugimoto T, Chihara K (2005) Statins modulate the levels of osteoprotegerin/receptor activator of NFκB ligand mRNA in mouse bonecell cultures. Horm Metab Res 37:589–592CrossRefPubMed

40.

Viereck V, Grundker C, Blaschke S, Frosch KH, Schoppet M, Emons G, Hofbauer LC (2005) Atorvastatin stimulates the production of osteoprotegerin by human osteoblasts. J Cell Biochem 96:1244–1253CrossRefPubMed

Titel: The Effects of Atorvastatin on the Prevention of Osteoporosis and Dyslipidemia in the High-Fat-Fed Ovariectomized Rats
verfasst von: Sien Lin
Jianping Huang
Ziwei Fu
Yanlong Liang
Haiyou Wu
Liangliang Xu
Yuxin Sun
Wayne Y. W. Lee
Tie Wu
Ling Qin
Liao Cui
Gang Li
Publikationsdatum: 01.06.2015
Verlag: Springer US
Erschienen in: Calcified Tissue International / Ausgabe 6/2015
Print ISSN: 0171-967X
Elektronische ISSN: 1432-0827
DOI: https://doi.org/10.1007/s00223-015-9975-7

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2015

Erratum to: Thyroid Hormone Attenuates Vascular Calcification Induced by Vitamin D3 Plus Nicotine in Rats

Systemic Administration of Lithium Improves Distracted Bone Regeneration in Rats

Adjusting Fracture Probability by Trabecular Bone Score

Low-Load Very High-Repetition Resistance Training Attenuates Bone Loss at the Lumbar Spine in Active Post-menopausal Women

Exploring the Interest in and the Usage of the Internet Among Patients Eligible for Osteoporosis Screening

Caffeic Acid Phenethyl Ester Abrogates Bone Resorption in a Murine Calvarial Model of Polyethylene Particle-Induced Osteolysis